Post-approval studies (Phase 4)Ended earlyNCT02241785
What this trial is testing
Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclerosis After Failure on Other Therapies
Who this might be right for
Relapsing Multiple Sclerosis
Biogen 47